troglitazone has been researched along with Intestinal Diseases in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, E | 1 |
| Li, C | 1 |
| Horn, N | 1 |
| Ajuwon, KM | 1 |
1 other study available for troglitazone and Intestinal Diseases
| Article | Year |
|---|---|
PPARĪ³ activation inhibits endocytosis of claudin-4 and protects against deoxynivalenol-induced intestinal barrier dysfunction in IPEC-J2 cells and weaned piglets.
Topics: Animals; Claudin-3; Claudin-4; Endocytosis; Epithelial Cells; Intestinal Diseases; Intestinal Mucosa | 2023 |